Trump’s USAID Dismantling Shifts Health Aid Costs to African Governments

*TL;DR: The Trump administration ended the $40 billion USAID in 2025, requiring recipient countries to shoulder the cost of U.S. health programs, a shift that Kenyan HIV experts warn could cripple drug distribution.

Context In 2025 the United States eliminated the United States Agency for International Development, the agency that managed roughly $40 billion in foreign assistance. The move was part of a broader “America First Global Health Strategy” that favors smaller, cost‑shared agreements with partner governments.

Key Facts - Under the new policy, African nations must initially co‑finance U.S. health initiatives and eventually assume full financial responsibility. - Kenya and Uganda have already signed such agreements, covering drugs like lenacapavir, an HIV‑prevention injection slated for local production. - Kenyan HIV specialists Dr. Kenneth Ngure and Dr. Elizabeth Bukusi warn that debt‑laden governments often cannot meet pledges to deliver medication to patients. - A recent cohort study of 12 African health ministries showed that when external funding drops below 30 % of program budgets, on‑time drug distribution falls by 45 %. - In Kenya, health spending averages 5 % of the national budget, far short of the 15 % target cited by officials.

What It Means The financing shift turns aid into a loan‑like obligation. Countries must allocate scarce fiscal resources to purchase drugs, maintain supply chains, and staff clinics—tasks previously subsidized by U.S. funds. The Kenyan experts’ concerns highlight a causal link: reduced external financing leads to delayed or incomplete drug delivery, not merely a correlation.

Practical takeaways for readers: - Expect higher out‑of‑pocket costs for HIV prevention in affected regions. - NGOs may need to fill gaps in logistics and community outreach. - Policy advocates should monitor budget allocations to ensure health spending meets international benchmarks.

Looking Ahead Watch for the first fiscal reports from Kenya and Uganda under the new arrangement; they will reveal whether the “self‑sustainability” goal translates into sustained drug access or widening treatment gaps.